Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
New words:
Antipsychotic, Apotex, Armitage, Axid, boxed, CATIE, Circuit, communicating, confidential, Dau, delivery, depreciated, earliest, Eli, ELSI, escrow, extend, extendible, faster, finance, gain, gathering, glucose, indirect, inquiry, Intervention, irrelevant, joined, label, lipid, master, mature, maturity, Mental, metabolism, monthly, National, Novopharm, omitted, Ortiz, parent, pen, pharmacy, responding, restitution, retirement, Robert, schizophrenia, showed, significantly, statistically, study, subsidiary, suicidal, superior, system, Tringali, uncommon, unconditionally, violative, working
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 the Eli Lilly and Company Bonus Plan, As Amended
- 10.2 Master Settlement Agreement
- 11 Statement Re: Computation of Earnings (Loss) Per Share
- 12 Statement Re: Computation of Ratio of Earnings
- 31.1 Rule 13A-14(A) Certification of Sidney Taurel
- 31.2 Rule 13A-14(A) Certification of Charles E. Golden
- 32 Section 1350 Certification
- 99 Cautionary Statement
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 11. STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE
(Unaudited)
Eli Lilly and Company and Subsidiaries
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2005 | 2004 | 2005 | 2004 | |||||||||||||
(Dollars and shares in millions except per- | ||||||||||||||||
share data) | ||||||||||||||||
BASIC | ||||||||||||||||
Net income | $ | 794.4 | $ | 755.2 | $ | 1,279.0 | $ | 1,812.5 | ||||||||
Average number of common shares outstanding | 1,088.6 | 1,084.8 | 1,087.6 | 1,083.0 | ||||||||||||
Contingently issuable shares | .3 | — | .2 | — | ||||||||||||
Adjusted average shares | 1,088.9 | 1,084.8 | 1,087.8 | 1,083.0 | ||||||||||||
Basic earnings per share | $ | .73 | $ | .70 | $ | 1.18 | $ | 1.67 | ||||||||
DILUTED | ||||||||||||||||
Net income | $ | 794.4 | $ | 755.2 | $ | 1,279.0 | $ | 1,812.5 | ||||||||
Average number of common shares outstanding | 1,088.6 | 1,084.8 | 1,087.6 | 1,083.0 | ||||||||||||
Incremental shares — stock options and contingently issuable shares | 2.8 | 4.4 | 3.5 | 5.9 | ||||||||||||
Adjusted average shares | 1,091.4 | 1,089.2 | 1,091.1 | 1,088.9 | ||||||||||||
Diluted earnings per share | $ | .73 | $ | .69 | $ | 1.17 | $ | 1.66 | ||||||||